SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-082641
Filing Date
2024-04-01
Accepted
2024-04-01 07:00:30
Documents
13
Period of Report
2024-03-28
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d812269d8k.htm   iXBRL 8-K 25482
  Complete submission text file 0001193125-24-082641.txt   147931

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA kymr-20240328.xsd EX-101.SCH 2852
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE kymr-20240328_lab.xml EX-101.LAB 17993
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kymr-20240328_pre.xml EX-101.PRE 11262
16 EXTRACTED XBRL INSTANCE DOCUMENT d812269d8k_htm.xml XML 3645
Mailing Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472
Business Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Filer) CIK: 0001815442 (see all company filings)

IRS No.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39460 | Film No.: 24805497
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)